Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental combo therapy for blood cancers shows early promise but trial halted

NCT ID NCT03940352

Terminated Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested two new drug combinations in 52 adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). One group received HDM201 plus MBG453, the other HDM201 plus venetoclax. The main goal was to check safety and find the right dose. The study was terminated early, so full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
HDM201 combined with either MBG453 or venetoclax
What this could lead to
If successful, this could point toward new combination treatments for AML and high-risk MDS.
What could go wrong
This was a very early (phase 1) trial that was terminated, so results are limited. The combinations may cause serious side effects and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA (AML) HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)

Contacts and locations

Locations

  • Duke University Medical Center .

    Durham, North Carolina, 27710, United States

  • Novartis Investigative Site

    Melbourne, Victoria, 3004, Australia

  • Novartis Investigative Site

    Helsinki, FIN 00290, Finland

  • Novartis Investigative Site

    Heidelberg, 69120, Germany

  • Novartis Investigative Site

    Würzburg, 97080, Germany

  • Novartis Investigative Site

    Milan, MI, 20132, Italy

  • Novartis Investigative Site

    Roma, RM, 00161, Italy

  • Novartis Investigative Site

    Singapore, 119228, Singapore

  • Novartis Investigative Site

    Madrid, 28041, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.